Close Menu

    Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    What's Hot

    Bukayo Saka injury news: Arsenal boss Mikel Arteta confirms hamstring surgery, forward expected to miss at least two months Football News

    December 27, 2024

    Scotty Scheffler: World No. 1 withdraws from PGA Tour season-opening golf game on Christmas Day with hand injury

    December 27, 2024

    Cristiano Ronaldo backs Manchester United manager Ruben Amorim for good performance but says club he still loves has ‘same’ problems Football News

    December 27, 2024
    Facebook X (Twitter) Instagram
    • About Us
    • Contact Us
    Facebook X (Twitter) Instagram YouTube
    Blowup News
    • Home
    • World News
    • Business
    • Politics
    • Entertainment
    • Tech
    • Crypto
    • Sports
    Blowup News
    Home»Business»Kangfang Biologics announced Ivonescimab combined with Ligufalimab as a first-line treatment for PD-L1-positive recurrent/metastatic head and neck squamous cell carcinoma at ESMO 2024
    Business

    Kangfang Biologics announced Ivonescimab combined with Ligufalimab as a first-line treatment for PD-L1-positive recurrent/metastatic head and neck squamous cell carcinoma at ESMO 2024

    ElcioBy ElcioSeptember 15, 2024No Comments3 Mins Read0 Views
    Facebook Twitter Pinterest LinkedIn Telegram Tumblr Email
    Share
    Facebook Twitter LinkedIn Pinterest Email

    Head-to-head Section 3 trial evaluating pembrolizumab has begun

    Hongkong, September 15, 2024 /PRNewswire/ — 2024 European Society for Medical Oncology (ESMO) Convention, it is coming Launched section 2 medical outcomes of its independently developed PD-1/VEGF bispecific antibody ivonescimab with or with out ligufalimab (anti-CD47 antibody AK117) for the first-line remedy of PD-L1-positive (CPS ≥ 1) relapse or metastatic head and neck squamous cell illness Most cancers (R/M HNSCC)

    As of knowledge cutoff date March 19, 2024The outcomes point out that for HNSCC the place speedy tumor shrinkage is extremely fascinating, the ivonescimab routine has demonstrated clinically significant reductions in tumor measurement. When mixed with ligufalimab, each tumor shrinkage and survival advantages have been additional improved in comparison with ivonescimab alone. Preliminary efficacy knowledge have been obtained utilizing ivonescimab alone and together with ivonescimab plus ligufalimab, exceeding beforehand disclosed PD-1 research.

    • The target response charge (ORR) was 30% within the ivonescimab monotherapy arm, whereas the ORR elevated to 60% within the ivonescimab plus ligufalimab arm. The illness management charge (DCR) was 80% within the ivonescimab monotherapy arm and improved to 90% within the ligufalimab arm. As of the time of the report, the anti-tumor efficacy of ivonescimab continues to be encouraging, with some sufferers demonstrating enchancment from steady illness (SD) to partial response (PR). The ORRs for ivonescimab monotherapy and ivonescimab plus ligufalimab have been 40% and 65%, respectively.
    • Median progression-free survival (mPFS) within the ivonescimab monotherapy arm was 5.0 months, however the 6-month PFS charge was not but reached. The median progression-free survival (mPFS) of the mixed ligfarimab group was 7.1 months, and the 6-month progression-free survival charge was 71.8%.
    • The protection profile of ivonescimab for first-line remedy of PD-L1-positive R/M HNSCC was manageable, with no treatment-related hostile occasions (TRAEs) resulting in drug discontinuation or dying in each the ivonescimab monotherapy and ivonescimab plus ligufalimab teams.

    Though programmed cell dying protein 1 (PD-1) inhibitors mixed with chemotherapy are authorised as first-line remedy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC), some sufferers don’t reply nicely to this method. The necessity for brand new remedy methods is highlighted. it is coming A section 3 medical research has been initiated to check ivonescimab plus ligufalimab with pembrolizumab within the first-line remedy of PD-L1-positive R/M HNSCC. This analysis has the potential to supply these sufferers with a brand new, extremely efficient immunotherapy possibility and should pave the way in which for developments in Most cancers Immunotherapy 2.0.



    Source link

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
    Elcio

    Related Posts

    DIY publisher Too Lost will host “Game From The GAUDS” music industry conference series in four U.S. cities

    September 28, 2024

    U.S. stocks: Dow Jones closes at record high, mild inflation report also boosts small stocks

    September 28, 2024

    Elon Musk’s X expected to come back online in Brazil ahead of elections

    September 28, 2024

    Philippines, US, Australia, Japan and New Zealand to hold joint maritime activities in South China Sea Reuters

    September 28, 2024

    Jonas Brothers’ father’s company acquires hit songwriter Julia Michaels’ catalog

    September 28, 2024

    Banking system liquidity returns to surplus; markets see signs of RBI softening stance

    September 27, 2024

    Comments are closed.

    Top Posts

    Liberal Party vs. Chase Oliver

    July 14, 202412 Views

    Interlock launches ThreatSlayer Web3 security extension and incentivized crowdsourced cybersecurity community

    June 27, 20247 Views

    Telemedicine company accused of being an Adderall pill factory says it will continue treating patients

    June 21, 20246 Views
    Don't Miss

    Bukayo Saka injury news: Arsenal boss Mikel Arteta confirms hamstring surgery, forward expected to miss at least two months Football News

    December 27, 2024

    Mikel Arteta has confirmed that Bukayo Saka has efficiently undergone surgical procedure on his hamstring…

    Scotty Scheffler: World No. 1 withdraws from PGA Tour season-opening golf game on Christmas Day with hand injury

    December 27, 2024

    Cristiano Ronaldo backs Manchester United manager Ruben Amorim for good performance but says club he still loves has ‘same’ problems Football News

    December 27, 2024

    World Darts Championship: Damon Heta’s nine-dart moves Stephen Bunting into fourth round but loses to Luke Woodhouse | World Darts Championship Darts news

    December 27, 2024
    Stay In Touch
    • Facebook
    • YouTube
    • TikTok
    • WhatsApp
    • Twitter
    • Instagram
    Latest Reviews
    Legal Pages
    • About Us
    • Contact Us
    • Disclaimer
    • DMCA Notice
    • Privacy Policy
    Most Popular

    Women in Defense initiative needs greater transparency and oversight

    November 4, 20243 Views

    Grayscale Ethereum Trust achieves zero outflows for the first time after ETF conversion

    August 13, 20243 Views

    Aaron Wan-Bissaka: West Ham sign Manchester United defender on seven-year contract Football News

    August 13, 20243 Views
    Our Picks

    Bukayo Saka injury news: Arsenal boss Mikel Arteta confirms hamstring surgery, forward expected to miss at least two months Football News

    December 27, 2024

    Scotty Scheffler: World No. 1 withdraws from PGA Tour season-opening golf game on Christmas Day with hand injury

    December 27, 2024

    Cristiano Ronaldo backs Manchester United manager Ruben Amorim for good performance but says club he still loves has ‘same’ problems Football News

    December 27, 2024
    Blowup News
    Facebook X (Twitter) Instagram Pinterest YouTube Dribbble
    • About Us
    • Contact Us
    • Disclaimer
    • DMCA Notice
    • Privacy Policy
    © 2025 ThemeSphere. Designed by ThemeSphere.

    Type above and press Enter to search. Press Esc to cancel.

    Manage Consent
    To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
    Functional Always active
    The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
    Preferences
    The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
    Statistics
    The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
    Marketing
    The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
    Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
    View preferences
    {title} {title} {title}